Abhimanyu Verma - 18 Mar 2026 Form 3 Insider Report for SOPHiA GENETICS SA (SOPH)

Role
Chief Technology Officer
Signature
/s/ Elimara Brunetto as Attorney-in-fact for Abhimanyu Verma
Issuer symbol
SOPH
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 09:46:11 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Verma Abhimanyu Chief Technology Officer C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND /s/ Elimara Brunetto as Attorney-in-fact for Abhimanyu Verma 18 Mar 2026 0002114540

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SOPH Ordinary Shares 125,813 18 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 31,847 $8.36 Direct F2
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 130,112 $4.72 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 182,927 $4.96 Direct F4
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 136,364 $3.29 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 80,762 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 122 ordinary shares from a March 30, 2022 grant vesting in equal monthly installments through March 30, 2026; (ii) 26,484 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 23,292 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 30,864 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
F2 The share option vests and becomes exercisable as to 25% of the ordinary shares on March 30, 2023, and then in equal monthly installments through March 30, 2026.
F3 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
F4 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
F5 The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney